Individualizing Treatment in the Management
of Type 2 Diabetes: Novel Therapies for
Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Lilly USA LLC Alliance,
Lilly USA LLC, and Sanofi

Description:
While the prevalence of diabetes continues to rise, a new generation of treatments has become available in the past few years. Despite new regimens, barriers to care, such as patient adherence and economic burden, still exist. It has been estimated that people diagnosed with diabetes, on average, have medical expenditures that are approximately 2.3 times higher than what expenditures would be in the absence of diabetes. The price tag associated with treatment of type 2 DM increases with disease severity, as more and more dollars are spent managing the significant comorbidities associated with advanced type 2 DM. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments for Type 2 Diabetes have given healthcare professionals the ability to individualize care. New data and guideline updates offer best practices in regard to the role of mono and combination therapies. Treatments have become available that allow the individualization of T2DM management. There have been many questions in member surveys and past program evaluations about the best practices in regard to the role of combination therapies comprised of SGLT-2 inhibitors in the management of type 2 diabetes, and new data and guidelines updates showing the benefits and risks of these new therapies.

Upon Completion of this activity, participants will be able to:

  • Compare and contrast the safety, efficacy and mechanisms of action of current and emerging therapies for achieving individualized target goals in types 2 diabetes (T2DM)

  • Apply newly released clinical data and guidelines on combination therapies to practice regarding glycemic management in patients with T2DM

  • Assess the importance of customizing A1c goals based on individual patient characteristics

  • Recognize the most effective place in the T2DM treatment continuum for GLP-1 agonists, newer insulins and SGLT-2 inhibitors

  • Analyze barriers to effective and timely combination therapy initiation and implement strategies to overcome these barriers in T2DM management

  • Examine recent clinical data on the use of combination therapy to improve glycemic control and other cardiovascular risk factors in patients with T2DM
     

Faculty: Richard E. Pratley
Samuel E. Crockett Chair in Diabetes Research
Director, Florida Hospital Diabetes Institute
Senior Investigator and Diabetes Program Lead,
Translational Research Institute for Metabolism and Diabetes
Adjunct Professor, Sanford Burnham Medical Discovery Institute

Disclosure:

Dr. Pratley receives research support from Lexicon, Lilly, Merck, Novo Nordisk, Sanofi and Takeda; he services as a consultant to AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck, Novo Nordisk, Sanofi and Takeda. All honoraria is directed toward a non-profit which supports education and research. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Lilly USA LLC Alliance,
Lilly USA LLC, and Sanofi

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue